Immunogenicity of Bacillus anthracis Protective Antigen Domains and Efficacy of Elicited Antibody Responses Depend on Host Genetic Background
Open Access
- 1 July 2008
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 15 (7) , 1115-1123
- https://doi.org/10.1128/cvi.00015-08
Abstract
Neutralizing antibodies to Bacillus anthracis protective antigen (PA), a component of anthrax toxin, mediate protection against anthrax. PA is antigenically complex and can elicit protective and nonprotective antibodies. Furthermore, vaccinated individuals demonstrate considerable variability in their antibody responses to PA. To explore the relationship between PA structure and antigenicity, we produced Escherichia coli strains expressing full-length PA (PA1-4), domains 2 to 4 (PA2-4), domain 1, (PA1), and domain 4 (PA4) and evaluated the immunogenicities and protective efficacies of the protein fractions in four mouse strains (strains A/J, BALB/c, C57BL/6, and Swiss Webster). Immunization with PA1-4 resulted in significantly higher lethal toxin-neutralizing antibody titers than immunization with any recombinant protein (rPA) fraction of PA. The magnitude and neutralizing capacity of the antibody response to full-length PA and its fragments varied depending on the mouse strain. We found no correlation between the antibody titer and the neutralizing antibody titer for A/J and Swiss Webster mice. In C57BL/6 mice, antibody titers and neutralization capacity correlated for two of four rPA domain proteins tested, while BALB/c mice displayed a similar correlation with only one rPA. By correlating the reactivity of immune sera with solvent-exposed linear peptide segments of PA, we tentatively assign the presence of four new linear B-cell epitopes in PA amino acids 121 to 150, 143 to 158, 339 to 359, and 421 to 440. We conclude that the genetic background of the host determines the relative efficacy of the antitoxin response. The results suggest that the variability observed in vaccination studies with PA-derived vaccines is a result of host heterogeneity and implies a need to develop other antigens as vaccine candidates.Keywords
This publication has 67 references indexed in Scilit:
- Analysis of epitope information related toBacillus anthracisandClostridium botulinumExpert Review of Vaccines, 2008
- Oral Administration of a Salmonella enterica -Based Vaccine Expressing Bacillus anthracis Protective Antigen Confers Protection against Aerosolized B. anthracisInfection and Immunity, 2007
- The Major Histocompatibility Complex Haplotypes Dictate and the Background Genes Fine-tune the Dominant versus the Cryptic Response Profile of a T-cell Determinant within a Native Antigen: Relevance to Disease Susceptibility and VaccinationScandinavian Journal of Immunology, 2007
- Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 ofBacillus anthracisprotective antigenFEMS Immunology & Medical Microbiology, 2006
- A Monoclonal Antibody to Bacillus anthracis Protective Antigen Defines a Neutralizing Epitope in Domain 1Infection and Immunity, 2006
- Cytokine Response and Survival of Mice Immunized with an Adenovirus Expressing Bacillus anthracis Protective Antigen Domain 4Infection and Immunity, 2006
- Dominant-Negative Mutants of a Toxin Subunit: An Approach to Therapy of AnthraxScience, 2001
- AnthraxNew England Journal of Medicine, 1999
- In vitro correlate of immunity in an animal model of inhalational anthraxJournal of Applied Microbiology, 1999
- Genetic Susceptibility to the Induction of Murine Experimental Autoimmune Orchitis (EAO) without Adjuvant. I. Comparison of Pathology, Delayed Type Hypersensitivity, and AntibodyClinical Immunology and Immunopathology, 1993